Payment overview · 2025
General Payments
$1,337.86
43 reported records · 8 companies
Healthcare provider profile · identity verified
Kirk Lee Jackson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DECATUR, AL · NPI 1316977945
Verified facts
What the public records show
CMS Open Payments records show Kirk Lee Jackson, M.D. received $1,337.86 in general payments during 2025 across 43 reported records.
Insulet Corporation accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $457.39 | 34.2% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $341.57 | 25.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $235.99 | 17.6% | 21 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $161.25 | 12.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $66.22 | 5.0% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 3.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.21 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.73 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,295.36 | 42 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $457.39 | 7 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $341.57 | 7 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $161.25 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $161.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $146.63 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $97.37 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $74.15 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $66.22 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 271 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 53 |
| Alprazolam | Alprazolam | 239 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 178 | 44 |
| Omeprazole | Omeprazole | 149 | 30 |
| Trazodone Hcl | Trazodone Hcl | 140 | 22 |
| Mounjaro | Tirzepatide | 135 | 22 |
| Furosemide | Furosemide | 130 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 25 |
| Gabapentin | Gabapentin | 108 | 15 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 82 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 15 |
| Potassium Chloride | Potassium Chloride | 75 | 18 |
| Azithromycin | Azithromycin | 74 | 51 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Eliquis | Apixaban | 73 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Losartan Potassium | Losartan Potassium | 70 | 16 |
| Bupropion Xl | Bupropion Hcl | 63 | 11 |
| Metformin Hcl | Metformin Hcl | 63 | 17 |
| Ozempic | Semaglutide | 63 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 12 |
| Irbesartan | Irbesartan | 55 | 15 |
| Prednisone | Prednisone | 54 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Famotidine | Famotidine | 49 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 11 |
| Montelukast Sodium | Montelukast Sodium | 46 | 12 |
| Allopurinol | Allopurinol | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 19 |
| Humalog | Insulin Lispro | 44 | 12 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Lisinopril | Lisinopril | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 41 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 22 |
| Fluconazole | Fluconazole | 25 | 15 |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 11 |
| Novolog | Insulin Aspart | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Mupirocin | Mupirocin | 21 | 15 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,337.86 · 43 records | Insulet Corporation | AFREZZA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Korlym, NURTEC ODT, OMNIPOD, Ozempic, RECORLEV, Rybelsus, Wegovy, XYOSTED, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error